RESEARCH TOPIC An In-depth-study of OTC medicine segment of Indian Pharmaceutical Industry with special emphasis on consumer behavior RESEARCH OBJECTIVES Macro objective To study the Indian Pharmaceutical Industry as a whole Micro objectives To understand the consumer’s attitude towards OTC products of the pharmaceutical industry To understand the healthcare products’ contribution and also its effects on pharmaceutical market To determine the extent to which the respondents prefer self-medication
Premium Pharmaceutical industry Pharmacology Generic drug
The case consists of two major pharmaceutical companies that joint to collaborate their research and pharmaceutical technologies to start a joint venture in India. Both have valuable resources that have benefited both companies during the joint venture. Now both are questioning if there is still any value in maintaining the joint venture in India and will be deciding what will be the best route to take. Ranbaxy Laboratories wants to be bought out‚ but Eli Lilly is worried of the financial implications
Premium Generic drug Pharmaceutical industry Clinical trial
OBJECTIVE: Through this study‚ we have tried to compare and analyse the following 3 ratios for 5 pharmaceutical companies’ vis-à-vis the industry average for these ratios. 1. Debt-Equity ratio‚ 2. Current ratio‚ and 3. Interest coverage ratio The 5 companies analysed include: 1. Vivimed Labs 2. Anuh Pharma 3. Tonira Pharma 4. Lincoln Pharmaceuticals 5. Dishman Pharmaceuticals & Chemicals FACTS AND ASSUMPTIONS: As for the industry averages and industry best ratios
Premium Pharmaceutical industry Pharmacology Pharmacy
Brian Lam A Critique of Strong Patent Protection Abstract In this paper‚ I attempt to analyze the negatives and positives of patent protection. The discussion will include an analysis of impact to firms and profits‚ particularly in the pharmaceutical sector‚ their innovations as a result‚ and the ultimate impact to society. Traditionally‚ it is believed that stringent patent regulations hurt the profits of large biotechnology companies‚ giving them less of an incentive to innovate. As a result
Premium Generic drug Patent Pharmaceutical industry
infection. By the year 2010 it is projected that the infected will reach above 60 million‚ possibly as high as 110 million (Beauchamp‚ 2004). There is a pharmaceutical drug that has been documented as having successfully beaten HIV‚ but why are the infected numbers still so high? With the number increasing literally per day‚ the government and pharmaceutical businesses have decided to capitalize on their drug therapies. The U.S. National Cancer Institute was actually able to discover a drug referred to
Premium HIV Immune system AIDS
Approach." AARHUS School of Business. Apr. 2011. Web. 20 Sept. 2011. . 4. David‚ Forest. "09 Pfizer." Scribd. Web. 03 Dec. 2011. . 5. "Diversity and Pfizer | Pfizer: the World ’s Largest Research-based Pharmaceutical Company." Pharmaceutical Company | Pfizer: the World ’s Largest Research-based Pharmaceutical Company. Web. 07 Dec. 2011. . 6. EZ Proxy Login. Web. 07 Dec. 2011. . 7. Joni‚ Saj-nicole. "Getting Beyond The Corporate Culture At Pfizer - Forbes.com." Information for the World ’s Business Leaders
Premium Pharmaceutical industry Pharmacology Strategic management
zyme-159068 *L’express ‚ http://lexpansion.lexpress.fr/entreprise/pourquoi-sanofi-a-interet-a-racheter-genzyme_236797.html * http://connection.ebscohost.com/c/articles/22317987/sanofi-aventis-bristol-myers-squibb-plavix-threat-looms-nearer * Pharmaceutical Case Study – Sanofi -Aventis ; Agility
Premium Pharmaceutical industry
at increasing diversity in the portfolio by becoming stronger in Bayer Cropscience in India. 2. Could Bayer have avoided the compulsory license (CL)? Identify and assess possible (evaluation criteria) market strategies for multinational pharmaceutical companies to achieve overall market success in emerging markets. (max. 3 slides) (25%) Also‚ there are talks of expanding that collaboration and bring in R&D and take some of their products either from Bayer or Zydus Cadila into other emerging
Premium Patent Pharmaceutical industry Pharmacology
affiliated with the pharmaceutical and praise the drug that the company wants to endorse. When these companies get articles published about their drug its free advertising. So when other doctors read the article their actually looking at an advertisement but they don’t know it. These medical journals are supposed to be unbiased and legitimate. This is undermining why these medical journals are published and taken so seriously. In my opinion this is the worst thing a pharmaceutical company can
Premium Medicine Pharmacology Pharmaceutical drug
market diversity. The following paper will discuss how mergers and acquisitions have affected the way in which companies do business. Business Ethics and Legal Issues The federal antitrust enforcers are investigating whether a multinational pharmaceutical company with two firms‚ one in the United States and one in Brazil‚ has attempted to diminish the impact of generic competition to one of its most profitable prescription drugs‚ Celexa. This anti-depressant drug is the company’s best seller‚
Premium Pharmacology Generic drug Pharmaceutical industry